Topical application of autologous serum for the treatment of late-onset aqueous oozing or point-leak through filtering bleb.
OBJECTIVE
To evaluate the efficacy of topical autologous serum application to stop aqueous oozing or point-leak through filtering bleb after trabeculectomy.


METHODS
A total of 21 consecutive eyes with oozing and 21 eyes with a point-leak through a functional bleb after trabeculectomy with 5-fluorouracil or mitomycin C were enrolled in this randomized, case-control study. In eyes randomly assigned to the serum group, an antibiotic and the autologous serum, which was sterilely diluted to 20% with physiological saline, were topically applied four times a day for up to 12 weeks. In eyes assigned to the control group, the antibiotic alone was applied according to the same protocol. Intraocular pressure (IOP) and the presence of oozing or a point-leak were tested before and every 2 weeks after starting the treatments.


RESULTS
In the serum and control groups, oozing stopped in 62.5 and 0% of eyes, respectively (P=0.003), and point-leaks stopped in 27.3 and 18.2%, respectively (P>0.9). IOP significantly increased from 10.0+/-3.2 (mean+/-standard deviation) to 11.8+/-3.3 mmHg in eyes in which oozing stopped (P=0.066), and from 11.4+/-2.7 to 15.4+/-2.3 mmHg in eyes in which a point-leak stopped (P=0.042).


CONCLUSIONS
Autologous serum application was significantly effective to stop aqueous oozing but not point-leaks. Stopping oozing or point-leaks was significantly associated with an increase in IOP.
Matsuo
H
H
1Department of Ophthalmology, University of Tokyo, Graduate School of Medicine, Bunkyo-ku, Tokyo 113-8655, Japan.
Tomidokoro
A
A
Tomita
G
G
Araie
M
M
D000287:Administration, Topical; D000963:Antimetabolites / Q000009:adverse effects; D001082:Aqueous Humor / Q000378:metabolism*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005260:Female; D018463:Filtering Surgery / Q000009:adverse effects; D005901:Glaucoma / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D044967:Serum; D018709:Statistics, Nonparametric; D014130:Trabeculectomy / Q000009:adverse effects*; D016896:Treatment Outcome
D000963:Antimetabolites